PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...
DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial ...
LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...
Collecting and documenting disability status at an Enhancing Oncology Model site: Outcomes of an ASCO Quality Training Project. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care ...
Three years ago, 10 Ascension Seton hospitals made a change in the type of medication they gave people experiencing an ischemic stroke. The outcomes of that switch have now been published in the ...
Alteplase was paid for by the patients, who later received various degrees of reimbursement from the Chinese social security system. In most instances, the patients or their families had to either ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results